Last Updated: July 2026
Published by: oncosolution — a specialist oncology medicine supplier serving patients, pharmacies, and distributors worldwide.
Medical Review: Reviewed by Dr. Farhan Hossain, MBBS, MD (Oncology)
Content Basis: This article is based on official prescribing information, product monographs, and regulatory product documentation from CDSCO and DGDA (Directorate General of Drug Administration, Bangladesh).
Sources: accessdata.fda.gov, accessdata.fda.gov, accessdata.fda.gov, drugs.com, drugs.com, medex.com.bd
Key Takeaways
Erdafitinib is a targeted FGFR tyrosine kinase inhibitor approved for adult patients (18 years and older) with locally advanced or metastatic urothelial carcinoma carrying susceptible FGFR3 or FGFR2 genetic alterations after prior platinum-based chemotherapy.
Molecular testing using an FDA-approved companion diagnostic is a mandatory prerequisite before initiating Erdafitinib therapy — patient selection depends entirely on confirmed FGFR gene alterations.
Two Bangladeshi-manufactured brands — Erdanib (Drug International Ltd.) and Erdafixen (Everest Pharmaceuticals Ltd.) — are available for export to India in 3 mg, 4 mg, and 5 mg color-coded film-coated tablet strengths.
Known serious adverse effects include severe hyperphosphatemia and soft tissue mineralization, ocular toxicity, and embryo-fetal toxicity; common effects include hyperphosphatemia, diarrhea, nausea, fatigue, and rash, among others.
Erdafitinib is metabolized via CYP3A4, requiring prescribers to review concomitant medications for potential drug-drug interactions before and during treatment.
Indian hospitals, oncology centers, and licensed distributors can source Erdanib and Erdafixen directly from us; buyers should confirm appropriate CDSCO import authorization before initiating procurement.
What Is Erdafitinib and What Condition Does It Treat?
Erdafitinib is an antineoplastic agent classified as a fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor. It is approved for the treatment of adult patients — aged 18 years and older — with locally advanced or metastatic urothelial carcinoma that carries susceptible FGFR3 or FGFR2 genetic alterations. Specifically, the indication covers patients whose disease has progressed during or following at least one line of prior platinum-containing chemotherapy, including progression within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
Urothelial carcinoma originates in the urothelium, the tissue lining the bladder and urinary tract. In its locally advanced or metastatic form, the disease presents significant treatment challenges, particularly after platinum-based regimens have failed. A subset of these patients harbor FGFR3 or FGFR2 genetic alterations — mutations or fusions — that drive tumor growth through aberrant FGFR signaling pathways.
Erdafitinib addresses this oncogenic driver directly. Its pharmacological activity is exerted in FGFR-driven activated cancerous cell lines, making it a targeted therapeutic option for a genetically defined patient population. Because eligibility depends on confirmed FGFR gene alterations, molecular testing is a prerequisite before therapy can be initiated. Indian oncology centers and procurement teams sourcing erdafitinib tablets supplier options should be aware of this companion diagnostic requirement.
Clinical Evidence Note: FDA approval documentation establishes that patient selection must be based on validated companion diagnostic testing to identify susceptible FGFR alterations before treatment initiation.
Available Brands: Erdanib and Erdafixen from Bangladesh
We source and export two Bangladeshi-manufactured brands of erdafitinib to India: Erdanib (Drug International Ltd., Bangladesh) and Erdafixen (Everest Pharmaceuticals Ltd., Bangladesh). Both brands are manufactured in Bangladesh and are available for export to Indian hospitals, oncology centers, pharmacies, and licensed distributors.
Erdafitinib is formulated as film-coated tablets and is available in three strengths, each distinguished by a specific color for easy identification:
- 3 mg tablet — yellow film-coated tablet
- 4 mg tablet — orange film-coated tablet
- 5 mg tablet — brown film-coated tablet
Both Erdanib and Erdafixen are supplied in these three strengths. The color-coding system supports accurate dispensing and patient safety in clinical settings.
As a Bangladeshi pharmaceutical exporter, we do not source or distribute Indian-manufactured brands or originator products. Our supply chain is exclusively built around Bangladeshi-manufactured brands, ensuring that Indian buyers receive products with clear, traceable manufacturing origins. Procurement teams at Indian hospitals and specialty pharmacies can contact us directly to confirm current stock availability for either brand across all three tablet strengths. We do not supply any brands other than those manufactured in Bangladesh, and we do not represent or distribute brands from any other country of origin.
Mechanism of Action: How Erdafitinib Works
Erdafitinib is a potent fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor. Its pharmacological activity is exerted specifically in FGFR-driven activated cancerous cell lines. By inhibiting FGFR tyrosine kinase activity, erdafitinib disrupts the aberrant intracellular signaling cascades that promote tumor cell proliferation and survival in patients whose cancers harbor susceptible FGFR3 or FGFR2 genetic alterations.
FGFR alterations — including mutations and gene fusions — result in constitutively active receptor signaling, which drives oncogenic behavior in a subset of urothelial carcinoma tumors. Erdafitinib’s targeted mechanism is therefore only clinically relevant in patients with confirmed susceptible alterations in these genes.
Prior to initiating therapy, confirmation of FGFR gene alterations must be established using an FDA-approved companion diagnostic test. This biomarker-driven approach ensures that treatment is directed at patients most likely to derive clinical benefit. Healthcare providers and oncology procurement teams should factor this mandatory pre-treatment testing requirement into patient selection and supply planning workflows. The companion diagnostic requirement is a regulatory and clinical prerequisite, not an optional step, and it applies regardless of the clinical setting in which erdafitinib is prescribed.
Side Effects of Erdafitinib
The following adverse reactions have been reported with erdafitinib. Patients and caregivers should discuss the full side effect profile with their treating physician before and during therapy.
Common side effects include:
- Hyperphosphatemia
- Hypocalcemia
- Diarrhea
- Nausea
- Fatigue
- Rash
- Alopecia
- Stomatitis
All clinical management of adverse reactions must be directed by the treating physician in accordance with the official prescribing information.
Important Clinical Considerations and Side Effect Profile
Healthcare providers and procurement teams should be familiar with the established safety profile of erdafitinib when evaluating it for formulary inclusion or patient supply.
Serious adverse effects include severe hyperphosphatemia, ocular toxicity, embryo-fetal toxicity, and infertility. Ocular toxicity warrants particular attention, as it may require ophthalmologic evaluation and management during the course of treatment.
Erdafitinib is metabolized via the CYP3A4 pathway, which has implications for drug-drug interactions. Prescribers should review concomitant medications for potential interactions involving CYP3A4 inducers or inhibitors.
Regarding reproductive safety: females of reproductive potential must use effective contraception during treatment and for one month after the last dose. Additionally, females should be advised not to breastfeed during treatment and for one month after the last dose.
All dosing decisions, regimen adjustments, and clinical management must be directed by the treating physician in accordance with the official prescribing information.
Regulatory Context: Erdafitinib Approval and India Market Access
Erdafitinib received FDA approval in 2019 for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma harboring susceptible FGFR3 or FGFR2 genetic alterations that has progressed after prior platinum-containing chemotherapy. This approval marked a significant milestone in biomarker-driven oncology therapy for urothelial carcinoma. In the global context, the originator product Balversa established the clinical and regulatory foundation upon which the broader therapeutic category has developed.
In India, the Central Drugs Standard Control Organisation (CDSCO) — accessible at cdsco.gov.in — is the national regulatory authority responsible for drug import approvals, market authorization, and licensing. Drugs not yet granted full market authorization in India may be accessible through special import permissions or named patient supply pathways, subject to CDSCO guidelines and applicable import regulations. Indian hospitals, oncology centers, and licensed importers should consult with regulatory affairs professionals to determine the appropriate import pathway for erdafitinib in their specific procurement context.
As a Bangladeshi exporter, our role is to facilitate the supply of Bangladeshi-manufactured erdafitinib brands — Erdanib and Erdafixen — to Indian healthcare buyers. We work with hospitals, specialty pharmacies, and licensed distributors to support the documentation and logistics requirements associated with cross-border pharmaceutical procurement. Indian procurement teams are encouraged to engage with us early in the sourcing process to align on regulatory documentation needs and supply timelines.
Regulatory Compliance Note: Import authorization requirements vary based on the specific regulatory pathway utilized. Buyers should verify their CDSCO compliance status before initiating procurement to ensure uninterrupted supply chain operations.
How to Source Erdafitinib Tablets for India: Our Export Process
We are a Bangladeshi pharmaceutical supplier specializing in the export of oncology medicines to India. For erdafitinib, we supply two Bangladeshi-manufactured brands — Erdanib and Erdafixen — available in 3 mg, 4 mg, and 5 mg film-coated tablet strengths.
Our export process is designed to support Indian healthcare procurement teams, including hospitals, oncology centers, specialty pharmacies, and licensed pharmaceutical distributors. The typical procurement workflow involves the following steps:
- Inquiry submission: Buyers contact us specifying the brand, strength, and quantity required.
- Documentation coordination: We assist with the preparation of export documentation, including invoices, packing lists, certificates of origin, and any additional paperwork required by the consignee or Indian import authorities.
- Consignee requirements: Indian buyers must hold the appropriate import licenses or permissions as required under CDSCO regulations. We recommend buyers confirm their import authorization status before placing orders.
- Logistics and shipment: We coordinate shipment from Bangladesh to the buyer’s designated delivery address in India, working with established freight and customs clearance partners.
Indian procurement teams seeking a reliable erdafitinib tablets supplier for FGFR-altered urothelial carcinoma cases are encouraged to contact us directly. We provide availability confirmations, export timelines, and full documentation support to facilitate compliant and efficient procurement.
Service Commitment: Our export team maintains responsive communication channels to support time-sensitive oncology procurement requirements.
Contact Us to Inquire About Erdafitinib Availability
Indian hospitals, oncology centers, specialty pharmacies, and licensed distributors are welcome to reach out to us for procurement inquiries regarding Erdanib and Erdafixen — our Bangladeshi-manufactured erdafitinib tablet brands available in 3 mg, 4 mg, and 5 mg strengths.
We provide export documentation support, availability confirmations, and logistics coordination for shipments to India. Contact us today to initiate your procurement inquiry and receive full sourcing assistance from our team.
Frequently Asked Questions
Who is eligible to receive erdafitinib treatment?
Erdafitinib is approved for adult patients aged 18 years and older with locally advanced or metastatic urothelial carcinoma whose tumors carry susceptible FGFR3 or FGFR2 genetic alterations and whose disease has progressed after at least one prior platinum-containing chemotherapy regimen. Confirmed molecular testing using an FDA-approved companion diagnostic is required before therapy can begin. Eligibility is therefore defined by both clinical history and a specific genetic profile.
What are the common and serious side effects associated with erdafitinib?
Common side effects include hyperphosphatemia, diarrhea, nausea, fatigue, rash, alopecia, and stomatitis, among others. Serious adverse effects include severe hyperphosphatemia, ocular toxicity, embryo-fetal toxicity, and infertility, with ocular toxicity potentially requiring ophthalmologic evaluation during treatment. Patients and caregivers should discuss the full side effect profile with their treating physician before starting therapy.
Are there any special precautions for women of reproductive age taking erdafitinib?
Females of reproductive potential must use effective contraception during treatment and for one month after the last dose due to the risk of embryo-fetal toxicity. Breastfeeding is also not recommended during treatment and for one month after the last dose. Patients should discuss reproductive safety planning with their oncologist before starting therapy.
Which erdafitinib brands do you supply for export to India, and what strengths are available?
We supply two Bangladeshi-manufactured brands — Erdanib and Erdafixen — both available in 3 mg, 4 mg, and 5 mg film-coated tablet strengths. These are the only brands we source and export; we do not supply Indian-manufactured or originator products. Indian buyers can contact us directly to confirm current stock availability across all three strengths.
What does the procurement process look like for Indian hospitals or pharmacies sourcing erdafitinib from Bangladesh?
The process begins with an inquiry specifying the brand, strength, and quantity required, after which we assist with export documentation including invoices, packing lists, and certificates of origin. Indian buyers must hold the appropriate import licenses or permissions under CDSCO regulations before placing orders. We coordinate logistics and shipment from Bangladesh and recommend engaging with us early to align on regulatory documentation and supply timelines.
- 1. www.accessdata.fda.gov
- 2. www.accessdata.fda.gov
- 3. www.accessdata.fda.gov
- 4. www.drugs.com
- 5. www.drugs.com
- 6. medex.com.bd
Access This Medicine Through oncosolution
We are a specialist oncology medicine supplier delivering to patients, pharmacies, hospitals, and distributors worldwide. Contact us for availability and sourcing support.
We do not publish prices online. All pricing is provided directly by our specialist supply team on request.
Medical Information Notice: This content is for informational purposes only and is based on official pharmaceutical product documentation. It does not constitute medical advice. Patients should consult their doctor or pharmacist before taking any medication.
Regulatory Disclaimer: Sourcing and distribution are subject to regional import regulations, quotas, and verified medical prescriptions where applicable. Pricing and availability are subject to change without notice.
Content Currency: This article was last reviewed and updated in July 2026. Regulatory approval statuses and product availability are subject to change; readers are advised to consult official regulatory databases for the most current information.